Bengali
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Home-base Kidney Care in Zuni Indians

কেবল নিবন্ধিত ব্যবহারকারীরা নিবন্ধগুলি অনুবাদ করতে পারবেন
প্রবেশ করুন - নিবন্ধন করুন
লিঙ্কটি ক্লিপবোর্ডে সংরক্ষিত হয়েছে
স্থিতিসমাপ্ত
স্পনসর
University of New Mexico
সহযোগী
Zuni Tribal Administration
Zuni comprehensive Community Health Center, Indian Health Services

কীওয়ার্ডস

বিমূর্ত

People reach End Stage Renal Disease (ESRD) due to progressive chronic kidney disease (CKD). CKD is associated with increased risks for heart disease and death. The burden of chronic kidney disease is increased among minority populations compare to Caucasians. The Zuni Indians are experiencing an epidemic of chronic kidney disease is due primarily to the high rates of obesity and diabetes. The present study entitled Home-Based Kidney Care is designed to delay / reduce rate of ESRD by early interventions in CKD. Investigators propose to assess the safety and efficacy of conducting a full-scale study to determine if home based care delivered by a collaborative team composed of community health workers and University of New Mexico faculty will decrease the risk for the development and the progression of CKD.

বর্ণনা

Hypothesis: (1) The Zuni Health Initiative (ZHI) can integrate an innovative approach to Home based kidney care (HBKC) utilizing tribal Community Health Representatives (CHRs), Point of Care (POC) technology, telemedicine and motivational messaging in conjunction with patient preferences and Patient Activation Measures (PAM) into the chronic care model to improve the detection and treatment of Chronic Kidney Disease (CKD) and related risk factors; (2) This model is generalizable to other high-risk communities e.g., Hispanic and American Indians in Guadalupe, AZ being studied by NIDDK, NIH-Phoenix.

Specific Aim 1: Re-phenotype prior participants, to identify incident cases of CKD, estimate progression rates, and identify participants for the proposed study of HBKC;

Specific Aim 2: Conduct a pilot study of HBKC in 120 people. Randomize households in a 1:1 allocation to usual care versus HBKC. Compare the changes in Patient Activation measure (PAM), Adherence, BP, weight, HbA1c, UACR, eGFR and lipid profiles between the two groups over the 1-year intervention period;

Specific Aim 3: Inform the design of the full-scale study by estimating anticipated recruitment, adherence and dropout rates, sample size and reassessing the approach;

Specific Aim 4: Assess the exportability of the HBKC model to Hispanics and American Indians in Guadalupe, AZ.

Study Outcomes: (1) The PAM and adherence; (2) Changes in clinical phenotypes including Cr, UACR, A1c, body weight, BMI, fasting glucose, blood pressure (BP), plasma lipids, and inflammatory markers; (3) Changes in the quantitative traits such as diet and scores from a battery of mental-health, self-efficacy, and quality of life instruments.

Health Impact: The active participation of the Zuni tribal leadership and IHS in this protocol, and the general affordability of Zuni native CHR personnel, render the outcomes that will be demonstrated by this proposal easily sustainable over the long term. If successful, this program has the potential to change best-practices for CKD progression and to reduce health disparities in a cost-effective and sustainable manner.

তারিখ

সর্বশেষ যাচাই করা হয়েছে: 11/30/2019
প্রথম জমা দেওয়া: 09/07/2016
আনুমানিক তালিকাভুক্তি জমা দেওয়া হয়েছে: 09/22/2016
প্রথম পোস্ট: 09/25/2016
সর্বশেষ আপডেট জমা দেওয়া হয়েছে: 12/02/2019
সর্বশেষ আপডেট পোস্ট: 12/03/2019
প্রথম জমা দেওয়া ফলাফলের তারিখ: 10/29/2018
প্রথম জমা দেওয়া কিউসির ফলাফলের তারিখ: 12/02/2019
প্রথম পোস্ট ফলাফলের তারিখ: 12/03/2019
আসল অধ্যয়ন শুরুর তারিখ: 09/30/2013
আনুমানিক প্রাথমিক সমাপ্তির তারিখ: 05/31/2016
আনুমানিক অধ্যয়ন সমাপ্তির তারিখ: 05/31/2016

অবস্থা বা রোগ

Chronic Kidney Disease

হস্তক্ষেপ / চিকিত্সা

Other: Education and Lifestyle Coaching

পর্যায়

-

বাহু গ্রুপ

বাহুহস্তক্ষেপ / চিকিত্সা
Experimental: Education and Lifestyle Coaching
Education and life style coaching includes: education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence
Other: Education and Lifestyle Coaching
Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters. Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month.
No Intervention: Usual care (UC) control arm
once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.

যোগ্যতার মানদণ্ড

বয়স অধ্যয়নের জন্য যোগ্য 21 Years প্রতি 21 Years
লিঙ্গ অধ্যয়নের জন্য যোগ্যAll
স্বাস্থ্যকর স্বেচ্ছাসেবীদের গ্রহণ করেহ্যাঁ
নির্ণায়ক

Inclusion Criteria:

- Clinical diagnosis of diabetes

- Clinical diagnosis of microalbuminuria

- Must be living in a household with more than 1 living participant

- Age 21 to 80 years

- Must have negative pregnancy test in women of child-bearing potential

Exclusion Criteria:

- Life expectancy < 1 year

- On dialysis

- With renal transplant

- Pregnancy or absence of reliable birth control in women of child-bearing potential

- Malignancy except non-melanoma skin cancer

- Blind

- Unwilling or unable to give informed consent.

ফলাফল

প্রাথমিক ফলাফল ব্যবস্থা

1. Patient Activation Measure (PAM) -13 Item Questionnaire [12 months follow-up minus baseline values]

Patient Activation Measure (PAM) questionnaire gives total score of activation as well as levels (stages) of patient activation. PAM total score can range form 0-100 with higher score reflecting higher level of activation in Patient health care. PAM levels (Stages) 1 through 4 with 1 being the lowest activation and 4 being the highest activation level. We collected data about Changes in PAM score as well as levels (stages) from baseline to 12 months of intervention and compare it to Usual care group.

2. Patient Activation Measure (PAM) Level Greater Than 2 [12 months follow-up]

Participants in an "Activated" category. Patient Activation Measure (PAM) questionnaire gives total score of activation as well as levels (stages) of patient activation. PAM total score can range form 0-100 with higher score reflecting higher level of activation in Patient health care. PAM levels (Stages) 1 through 4 with 1 being the lowest activation and 4 being the highest activation level. Level 1 labeled as patient being dis-engaged, Level 2 labeled as patient becoming aware of health condition but still struggling, level 3 labeled as patient is taking action and gaining control of their health care and level 4 labeled as maintaining behaviors and pushing forward - for our analysis purposes we classified participants into levels 3 and 4 (activated) and level 1 and 2 as not activated. We collected data about Changes in PAM score as well as levels (stages) from baseline to 12 months of intervention and compare it to Usual care group.

মাধ্যমিক ফলাফলের ব্যবস্থা

1. A1c [12 months minus baseline values]

Changes in clinical values

2. Diastolic Blood Pressure [12 months minus baseline values]

Changes in diastolic blood pressure on study.

3. Systolic Blood Pressure [12 months minus baseline values]

Changes in Systolic blood pressure over study.

4. Body Mass Index [12 months minus baseline values]

Changes in the value of body mass index (BMI)

5. Low-density Lipoprotein LDL Cholesterol [12 months minus baseline values]

Changes in serum LDL cholesterol on study

6. High-density Lipoprotein HDL Cholesterol [12 months minus baseline values]

Change in serum HDL cholesterol on study

7. Triglycerides [12 months minus baseline values]

Change in serum triglycerides on study

8. Serum Total Cholesterol [12 months minus baseline values]

Change in total cholesterol on study

9. High Sensitive C-reactive Protein-hsCRP [12 months minus baseline values]

Changes in the serum c-reactive protein on study

10. Serum Total Protein [12 months minus baseline values]

Change in total protein on study

11. eGFR [12 months minus baseline values]

Changes in estimated (via CKD-EPI) Glomerular Filtration Rate.

12. UACR [12 months minus baseline values]

change in urinary albumin to creatinine ratio on study.

13. KDQOL-Symptom/Problem [12 months minus baseline values]

Changes on study of symptom/problem list from quality of life (KDQOL-36). Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD). For all KDQOL scales, a higher score indicates better quality of life. All domain scales can range from 0-100.

14. KDQOL-EKD [12 months minus baseline values]

Changes in effects of kidney disease score from quality of life (KDQOL). Changes on study of effect of kidney disease from quality of life (KDQOL-36). Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD). For all KDQOL scales, a higher score indicates better quality of life. All domain scales can range from 0-100.

15. KDQOL-BKD [12 months minus baseline values]

Change on study of burden of kidney disease score from KDQOL-36. Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD). For all KDQOL scales, a higher score indicates better quality of life. All domain scales can range from 0-100.

16. KDQOL-SF12 Physical Score [12 months minus baseline values]

Changes on study of SF12 physical quality of life scale from the KDQOL-36. Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD). For all KDQOL scales, a higher score indicates better quality of life. All domain scales can range from 0-100.

17. KDQOL-SF12 Mental Score [12 months minus baseline values]

Change on study of SF12 mental quality of life scale from the KDQOL-36 Quality of life (QOL) was measured using the Kidney Disease Quality of Life-36 (KDQOL-36) survey, a kidney-disease-specific quality of life instrument that assesses five domains: general physical health (SF-12 Physical), mental health (SF-12 Mental), burden of kidney disease (BKD), disease symptoms problem list (SP), and effects of kidney disease (EKD). For all KDQOL scales, a higher score indicates better quality of life. All domain scales can range from 0-100.

18. 8-Item Morisky Score [12 months minus baseline values]

Change in Morisky total score on study.The 8-item Morisky scale is a validated scale designed to estimate the risk of medication non-adherence. The Scale of the total score ranges from 0 to 8. We only report a total score. For a reported scale, Zero reflects worse medication adherence and 8 reflects better medication adherence We didn't combine the subscales to compute a total score, but the total score does reflect the number of individual items that were endorsed.

আমাদের ফেসবুক
পেজে যোগদান করুন

বিজ্ঞানের দ্বারা সমর্থিত সবচেয়ে সম্পূর্ণ completeষধি ভেষজ ডেটাবেস

  • 55 ভাষায় কাজ করে
  • বিজ্ঞানের সহায়তায় ভেষজ নিরাময়
  • ইমেজ দ্বারা ভেষজ স্বীকৃতি
  • ইন্টারেক্টিভ জিপিএস মানচিত্র - অবস্থানের উপর গুল্ম ট্যাগ করুন (শীঘ্রই আসছে)
  • আপনার অনুসন্ধান সম্পর্কিত বৈজ্ঞানিক প্রকাশনা পড়ুন
  • তাদের প্রভাব দ্বারা herষধি গুল্মগুলি অনুসন্ধান করুন Search
  • আপনার আগ্রহগুলি সংগঠিত করুন এবং নিউজ রিসার্চ, ক্লিনিকাল ট্রায়াল এবং পেটেন্টগুলির সাথে আপ ডেট থাকুন

একটি লক্ষণ বা একটি রোগ টাইপ করুন এবং এমন গুল্মগুলি সম্পর্কে পড়ুন যা সহায়তা করতে পারে, একটি bষধি টাইপ করতে পারে এবং এর বিরুদ্ধে ব্যবহৃত রোগ এবং লক্ষণগুলি দেখতে পারে।
* সমস্ত তথ্য প্রকাশিত বৈজ্ঞানিক গবেষণার উপর ভিত্তি করে

Google Play badgeApp Store badge